posted on 2020-06-11, 14:59authored bySytze P Rensma, Thomas T van Sloten, Jennifer Ding, Sigurdur Sigurdsson, Coen DA Stehouwer, Vilmundur Gudnason, Lenore J Launer
<b></b><b>Objective: </b>Type 2 diabetes has been associated
with depression. However, the underlying pathophysiological mechanisms remain unknown.
Cerebral small vessel disease, a consequence of diabetes, may lead to
depression. Therefore, we evaluated
whether cerebral small vessel disease mediates the association between type 2 diabetes and higher depressive
symptoms.
<p><b>Research Design and
Methods: </b>We used longitudinal data
from the population-based Age, Gene/Environment
Susceptibility-Reykjavik Study, with
examinations from 2002/2006 and five years later. Type 2 diabetes was defined
as<b> </b>self-reported history of type 2 diabetes, use of blood glucose-lowering
drugs, or fasting blood glucose level ≥7.0 mmol/L. Cerebral small vessel
disease load was quantified in a composite score based on MRI-defined presence
of high white matter hyperintensity volume, low total brain parenchyma volume,
and subcortical infarcts, cerebral microbleeds and large perivascular spaces. 5-year
change in 15-item Geriatric
Depression Scale score (GDS-15) was measured between baseline and follow-up.</p>
<p><b>Results: </b>2,135
individuals without dementia and baseline depression were included (baseline age
74.5 years [SD 4.6], 1,245 [58.3%] women and 197 [9.2%] with diabetes). The GDS-15
score increased 0.4 points (SD 1.6) over time. Baseline diabetes was associated
with greater increase in GDS-15 score (β 0.337, 95%CI 0.094; 0.579), adjusted
for age, sex, education and cardiovascular risk factors. Baseline cerebral
small vessel disease and change of cerebral small vessel disease statistically
significantly mediated a part of this association.</p>
<b>Conclusions: </b>Type 2 diabetes is associated with a greater increase
in depressive symptoms score over 5 years, and cerebral small vessel disease in
part explains this association.<b> </b><b> </b>
Funding
This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. Van Sloten is supported by a VENI research grant (916.19.074) from The Netherlands Organization for Scientific Research (NWO) and The Netherlands Organization for Health Research and Development (ZonMw), and by a Dutch Heart Foundation research grant (2018T025). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.